Paragon 28 Inc. Aktie
6,95 €
Deine Einschätzung
Paragon 28 Inc. Aktie
Was spricht für und gegen Paragon 28 Inc. in den nächsten Jahren?
Pro
Kontra
News
Paragon 28 Reports First Quarter 2024 Financial Results and Reaffirms 2024 Net Revenue Guidance
Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the
Paragon 28 to Present at the Bank of America Securities 2024 Healthcare Conference
Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO, and Krissy Wright
Paragon 28 Announces CFO Transition, Provides Preliminary Unaudited Net Revenue for First Quarter 2024, and Reaffirms Net Revenue Guidance for Fiscal Year 2024
Paragon 28, Inc. (NYSE: FNA), (“Paragon 28” or “the Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Stephen Deitsch